GENE ONLINE|News &
Opinion
Blog

AAV Gene Therapy
Global Biotech Elites Gather to Explore Trends and Prospects of Cell and Gene Therapies
2023-08-09
2023 ASGCT Annual Meeting: Showcase of Exciting New Research, with a Focus on Clinical Applications
2023-06-02
Ginkgo Bioworks Adds StrideBio’s AAV Platform To Step Up Gene Therapy Development
2023-04-06
Cyagen, Neurophth Ink $140 Million Deal For AI-Designed AAV Capsids
2022-11-08
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Kriya Bags $270 Million Series C to Support Integrated Gene Therapies
2022-05-18
Astellas Ditches Gene Therapies, with Losses Exceeding $390 Million
2022-04-25
Astellas Reveals Early Safety Data of Gene Therapy for Pompe Disease
2022-02-09
Astellas Taps Dyno in $1.6+ Billion Deal to Develop AAV Gene Therapies
2021-12-02
Researchers Engineer “Mini” CRISPR-Cas System That Could Act as ‘Swiss Army Knife’ for Mammalian Genome Editing
2021-09-07
Serious Adverse Event in Study Participant Marks Latest Roadblock for Astellas’ Gene Therapy Trial
2021-09-03
George Church’s New Startup Engineers AAV Vectors that Evades Host Immune Responses
2021-02-17
uniQure’s Hemophilia B Gene Therapy Put on Clinical Hold by the FDA
2020-12-22
Is Bayer’s Entry to the Gene Therapy Market Worth it’s Investment?
2020-10-27
New ‘Minigene’ Insertion Approach Could Treat Rare Liver Disease in Mice
2020-02-15
LATEST
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
AstraZeneca’s Latest Moves in Pharmaceuticals in Q1 2024
2024-03-21
AI-Designed Antibodies: A Revolution in Antibody Drug Discovery
2024-03-20
Orchard Therapeutics’ Gene Therapy for Rare Neurological Disorder Wins FDA Approval
2024-03-20
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top